BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 10, 2017
View Archived Issues
Praeventix, Temple University identify 5-HT7 antagonists for treating IBD
Read More
Alnylam and Sanofi Genzyme initiate ATLAS phase III program for fitusiran
Read More
Novel compounds targeting transglutaminase-2 for renal cell carcinoma show promise
Read More
Recruitment expanded in phase II breast cancer trial of LiPlaCis
Read More
FDA approves Endari for sickle cell disease
Read More
Oncology Venture licenses PARP inhibitor from Eisai
Read More
Clearances for German phase I trial of IMP-321 in solid tumors
Read More
Inotek announces phase II topline results for trabodenoson/latanoprost in glaucoma
Read More
Biocartis and A*STAR's ETPL begin development of breast cancer assay
Read More
BioTech to pursue critical limb ischemia as first Procell indication based on pilot clinical data
Read More
Novan presents new data on SB-204 in adolescents
Read More
Oncolys BioPharma enrolls first patient in phase I study of Telomelysin in esophageal cancer
Read More
GlaxoSmithKline and Astex Therapeutics describe novel prostaglandin-D2 synthase inhibitors
Read More
Immatics initiates phase I ACTolog study
Read More
Redx Pharma patents Bruton tyrosine kinase inhibitors
Read More
Hangzhou Innogate Pharma presents novel CKD and/or HDAC inhibitors
Read More
Inotrem initiates phase II study of Motrem for septic shock
Read More
Bardoxolone methyl granted U.S. orphan drug status for Alport syndrome
Read More
FDA names entrectinib an orphan drug for NTRK fusion-positive solid tumors
Read More
Sirukumab named orphan drug in the U.S. for juvenile idiopathic arthritis
Read More
FDA designates tadekinig alfa an orphan treatment for Still's disease
Read More
Celgene's avadomide receives U.S. orphan status for hepatocellular carcinoma
Read More